This report describes a child with a severe phenotype of autoimmune lymphoproliferative syndrome (ALPS) who developed progressive disease requiring stem cell transplantation. This severe form of ALPS was associated with a novel Fas gene splice site mutation that resulted in functional deletion of exons 8 and 9. While this child shared many clinical features with previously described ALPS cases, including massive lymphadenopathy and circulating ␣␤ + CD3 + CD4 ؊ CD8 ؊ T cells, his disease progressed despite immunosuppressive therapy to a clinically aggressive oligoclonal lymphoproliferation which resembled a diffuse large cell non-Hodgkin's lymphoma. After partial remission was achieved with cytotoxic therapy the patient underwent BMT from an unrelated donor. This is the first reported case of ALPS in which BMT was successfully attempted for correction of a Fas deficiency.
BMT has been successfully used in the correction of genetically determined immunologic deficiencies, lymphoma and severe autoimmune disease. ALPS, a genetic disorder of apoptosis, can result in all three of these pathologic processes. For this reason when the patient described here developed life-threatening complications of Fas deficiency, correction by stem cell transplant was undertaken.
The genetically controlled mechanism of programmed cell death (apoptosis) plays an important role in thymic and peripheral selection of T and B lymphocytes. [1] [2] [3] Fas, a cell surface receptor localized to human chromosome 10q, 4, 5 interacts with Fas ligand to induce apoptosis. The human Fas gene has been characterized 6 and Fas mutations have been associated with symptoms reminiscent of murine models of inherited autoimmune disease, particularly lpr (lymphoproliferation) and gld (generalized lymphoproliferative disease) mutants which have well-defined Fas and Fas ligand gene defects, respectively. [7] [8] [9] [10] A variety of Fas mutations have been described in humans with an autoimmune lymphoproliferative syndrome (ALPS). 11, 12 In addition, Drappa et al 13 described several patients with ALPS-like disease characteristics who had been diagnosed previously with Canale-Smith syndrome and are now known to have Fas mutations.
In this report, we describe the clinical course in a patient with a novel Fas mutation who demonstrated a severe phenotype of ALPS. At 4 years of age, BMT was performed when life-threatening complications of his disease were no longer responsive to immunosuppression. Thirty months after BMT the patient remains free of disease, demonstrating that ALPS can be corrected by this form of therapy.
Materials and methods

Subject enrollment
These studies were done after Institutional Review Board approval and parental consent were obtained. Blood donated by parents and unrelated healthy normal adult controls was processed in parallel to patient samples in all assays. Table 1 provides an abbreviated summary of this patient's clinical course. This male patient presented at 3 months of age with severe Coombs negative hemolytic anemia. By 6 months of age, he developed hypersplenism and lymphadenopathy. Splenectomy and lymph node (LN) biopsy were performed. Histology of the 500 g spleen (normal 20 g) and a LN revealed an atypical lymphoproliferative process. The polymorphous cellular infiltrate consisted of immunoblasts, plasma cells and lymphocytes. Nodal architecture was preserved. No viral etiology was found.
Clinical history
Following splenectomy, the patient maintained a baseline WBC count of 30 000-40 000/l with marked atypical lymphocytosis. With minimal doses of steroids, his hemoglobin stabilized at approximately 10 g/dl. However, lymphadeno- + lymphocytes lacked CD4 and CD8 expression, and many showed loss of CD7. Gene rearrangement studies for Ig and TCR did not reveal monoclonal bands. Decreased mitogenic responses, decreased natural killer cell and cytotoxic T lymphocyte numbers and function as well as polyclonal B cell proliferation with hypergammaglobulinemia were documented on numerous occasions. Other clinical features included prominent eosinophilia, mild glomerulonephritis, urticarial rashes and chronic hypertriglyceridemia. Both chronic, diffuse pulmonary infiltration and hepatomegaly associated with mild hepatitis were attributed to lymphoid infiltration. At 30 months of age, progressive lymphadenopathy resulted in airway compression which responded to steroids.
At 41 months of age, severe pancytopenia developed and the patient became transfusion dependent. BM biopsy showed less than 1% hematopoietic cells, increased plasma cells and a few lymphoid aggregates with mild fibrosis. No specific autoantibodies were ever detected. Treatment with anti-thymocyte globulin (ATG), CsA, steroids and G-CSF was initiated with subsequent improvement in hematopoiesis.
Five months later while still receiving CsA, leukocytosis peaked at 90 000/l, predominantly lymphocytes, in association with progressive lymphadenopathy, recurrent anemia and thrombocytopenia along with increasing hypergammaglobulinemia. The peripheral blood smear showed markedly atypical, immature-appearing lymphocytes (28%) with cytoplasmic and nuclear blebbing. Double negative T cells (DNT) represented 51% of circulating CD3 + cells. Lymphocytosis failed to respond to 10 mg/kg/day prednisone for 3 days. Histopathology of a LN biopsy was consistent with diffuse, large cell (T cell) non-Hodgkin's lymphoma. Analysis of the LN showed 98% CD3 + T cells of which 78% were both CD4 and CD8 negative, and only 29% were CD7 positive. The CD3 + cells were ␣␤ TCR positive. Several faint non-germline bands were noted with the TCR J ␤ chain gene probe, suggesting an emerging oligoclonal pattern.
An additional attempt with immunosuppressive therapy using ␣-interferon failed. ) with CsA and MTX for GVHD prophylaxis. He engrafted rapidly after receiving an HLA-A minor mismatched, unrelated BM donor graft which was not T cell depleted. Early-onset grade III GVHD of the skin was successfully treated with steroids but grade IV GVHD of the GI tract required a prolonged course of methylprednisolone (30 mg/kg/day) plus FK506. Long-term immunosuppression included steroids and FK506. All immunosuppressive therapy was discontinued by 24 months post-BMT.
Two years post-BMT during a routine evaluation of immunologic parameters, he had an increased percentage of DNTs, 12% precisely, with the absolute number of CD3 + CD4 Ϫ CD8 Ϫ cells being 359/dl. All other immunologic parameters were within normal limits and no clinical consequences were evident. This sampling was the first taken after discontinuation of all immunosuppressive agents. Immunophenotyping 3 months later showed only 5% DNTs with the absolute number of DNTs being 112/dl.
The family history was notable in that this patient's father presented to his physician at 32 years of age with chronic fatigue, splenomegaly and abdominal lymphadenopathy. Polyclonal immunoglobulin (Ig) heavy chains were present in his urine without light chain Ig. Splenectomy was performed. Now 4 years later, the father has no clinical evidence of immunologic dysfunction. No other family members have been diagnosed with immunodeficiency, lymphoma, lymphoproliferative or autoimmune diseases.
cDNA preparation
PBLs were isolated from the patient, his parents and control individuals by Ficoll (Organon Teknika Corp, Durham, NC, USA). RNA was extracted using RNAzol B (TELTEST Inc., Friendswood, TX, USA). cDNA synthesis reaction mixtures (volume 30 l), containing 1 g RNA, 0.5 mm dNTPs, 25 units RNAsin (Promega, Madison, WI, USA), 0.35 g oligo d(t), 1 × reaction buffer supplemented with 1.5 mm MgCl 2 , 300 units MMLV reverse transcriptase and 1 mm DTT (Gibco/BRL, Gaithersburg, MD, USA), were incubated at 21°C for 10 min, 42°C for 60 min and 95°C for 5 min. cDNA samples were stored at Ϫ70°C until further use.
PCR amplification of cDNA
A Perkin Elmer (Norwalk, CT, USA) 9600 Thermal Cycler was used for all PCR amplifications. The following Fasspecific primer sets (5Ј-3Ј) were designed to amplify the entire length of Fas cDNA in three overlapping segments: A-Forward (For) ATGCTGGGCATCTGGACC, B-For ACCAAGTGCAAAGAGGAAGGA, C-For GCAGAA-AGCACAGAAAGGAAAAC, A-Reverse (Rev) GTTTTC-CTTTCTGTGCTTTCTGC, B-Rev TTCTGTTCTGCT-GTGTCTTGGA, C-Rev GACCAAGCTTTGGATTTC-ATTTC. ␤-2 microglobulin and interferon-␥ were amplified as controls. PCR reactions typically contained 1 × reaction buffer, 0.2 mm dNTPs, 0.3 mm primers, 1 × cresol red dye, 1 l cDNA and 0.25 U Tfl DNA polymerase (Epicentre Technologies, Madison, WI, USA) in 25 l volume. A 5 min hot start at 95°C was performed. Thirty-five to 40 cycles of denaturation at 95°C × l min, annealing at 54°C or 45°C (for cDNA or genomic DNA amplification, respectively) × 1 min and elongation at 72°C × 2 min were utilized; the final cycle included a 10 min extension at 72°C. Amplification products were electrophoretically separated on 3% agarose gels (3:1 High Resolution Blend; Amresco, Solon, OH, USA) and visualized following ethidium bromide staining. The identity of certain PCR amplification products were confirmed by digestion with the restriction enzymes DdeI and TaqI (Gibco/BRL).
Genomic Fas PCR amplification and cloning
Genomic DNA samples were prepared from PBLs by lysis in 100 l PCR buffer with non-ionic detergents (50 mm KCl, 10 mm Tris-HCl pH 8.3, 2.5 mm MgCl 2 , 0.1 mg/ml gelatin, 0.45% NP40, and 0.45% Tween 20) and Proteinase K (0.06 mg/ml) for 60 min followed by incubation at 95°C for 15 min. The following genomic primers (5Ј-3Ј) were used to amplify an approximately 800 bp fragment from the 3Ј end of intron 7-5Ј end of exon 9 of Fas: For CTTTCTCTGCTTCCATTTTT, Rev GTGGTGATATAT-TTACTCAAGTC. The PCR amplified fragments from this region were sequenced using dideoxy methods and an Applied Biosystems automated system (Foster City, CA, USA).
Direct cloning of the genomic Fas PCR products from the patient and both parents was performed using the Original TA Cloning Kit (Invitrogen, San Diego, CA, USA). Briefly, each PCR product was ligated into the PCR II vector and transformed into One Shot competent bacteria. Inserts were confirmed by restriction digestion of miniprepped plasmid DNA with EcoRI, followed by gel electrophoresis and ethidium bromide staining. Positive recombinant plasmid DNAs purified using Mini-Preparation kits (Qiagen Inc, Chatsworth, CA, USA) were sequenced using a 3Ј sequencing primer (5Ј-CGAACTGCCTGATAAAT-GCT-3Ј). Sequence comparisons were performed using MacVector computer software (IBI, New Haven, CT, USA).
Fas detection by flow cytometry
EBV-transformed cell lines from the patient, parents and a normal control were prepared as described 14 and were maintained in RPMI medium supplemented with 20% FBS and 1% penicillin and streptomycin. One million cells from each cell line were washed with PBS plus 2% FBS before resuspension in 50 l of PBS plus 2% FBS. Twenty l of PE-labeled anti-Fas Ab (PharMingen, San Diego, CA, USA) plus 10 l of FITC-labeled anti-CD19 Ab (Becton Dickinson, San Jose, CA, USA) were added to the cell suspension, followed by a 30 min incubation at 4°C in the dark. Antibody binding was analyzed using a Becton Dickinson FACSCalibur flow cytometer. Isotype-matched negative control Abs and Fas-negative cell lines were analyzed simultaneously.
Results
Fas mutation
Fas mRNAs were examined from patient and control cDNAs using three overlapping RT-PCR fragments (A, B, C). The patient showed smaller amplification fragments B and C as compared to normal individuals, whereas amplification of ␤-2-microglobulin and interferon-␥ gave similarly sized products from patient and control samples. Digestion of fragments B and C with both DdeI and TaqI restriction enzymes confirmed the authenticity of these products and identified the patient's defect as an approximately 25 bp deletion in the C-terminus (exons 7-9) of the Fas sequence. Direct sequencing of RT-PCR Fas fragment B in both 5Ј and 3Ј directions demonstrated deletion of the entire 25 bp exon 8 and frameshifting plus premature termination of exon 9 in the patient's as compared to normal cDNA (Figure 1a and b) .
To investigate whether the exon 8 and 9 effects were due to a mutation at a splice junction site, PCR fragments encompassing the intron 7, exon 8 and intron 8 region of Fas were amplified from genomic DNA and cloned by TA tailing. In order to eliminate the problem of directionality of the cloned fragment, a sequencing primer that hybridized to intron 8 and allowed sequencing backwards into exon 8 and intron 7 was designed. Six to 10 clones each from the patient and both parents were sequenced using this primer. The patient showed a point mutation (G-T) in one allele in the splice acceptor of intron 7 ( Figure 1c ). These results were confirmed by repeating the PCR amplification, TA cloning and sequencing of six additional clones. Both parents showed normal genomic Fas sequence at this site. Parental relationships were confirmed by HLA typing. As a result of this point mutation, exon 7 of the Fas transcript evidently was spliced directly to exon 9, causing omission of the 25 bp of exon 8 and a frameshift leading to translation of three alternative amino acids followed by premature termination early in exon 9 (Figure 1b) . Although the patient's second Fas allele was normal in this region, RT-PCR amplification using primers designed to generate 5Ј fragment A showed multiple bands in the patient but only a single band in both parents and normal controls (data not shown). Surface staining of EBV-transformed cell lines showed decreased expression of Fas in the patient and his father as compared to the mother and a normal unrelated control ( Figure 2 ). 
BMT outcome
At 40 months post-BMT, no signs or symptoms of this patient's primary disease were evident. Variable number tandem repeat (VNTR) analysis of BM confirmed persistence of complete donor engraftment, immunophenotyping of PBLs showed 5% DNT cells and CT scans revealed no lymphadenopathy.
Discussion
We describe a patient with a novel Fas mutation who developed a severe phenotype of ALPS. He showed CD3 + CD4 Ϫ CD8 Ϫ TCR ␣␤ + T cell lymphoproliferation in association with polyclonal B cell expansion, hypergammaglobulinemia, paraproteinemia, hemolytic anemia and eosinophilia. This atypical lymphoid proliferation progressed to aplastic anemia and then to resemble an aggressive, large cell (T cell) lymphoma. However, as in the lpr mouse model, this patient's atypical LPD was felt to represent end-stage LPD caused by defective Fas-Fas ligandmediated lymphocytic apoptosis and immune dysregulation, rather than a conventional malignancy. Interestingly, lpr mice were originally thought to represent an animal model of lymphoma. 15 The strong similarities between this human disease and that seen in lpr mice favored consideration of BMT as a potentially curative therapy, since the murine disease is corrected by BMT. 16, 17 Another indication for BMT in this patient was severe tri-lineage hematopoietic aplasia prior to and following chemotherapy. Accordingly, the patient underwent BMT, which to date appears to have corrected all aspects of his primary disease.
The unique severity of this patient's disease may be related to one or more of at least three factors. First, is the presence of molecular defects in both Fas alleles. Most other ALPS patients reported have been heterozygous for a defective Fas allele, with the exception of a patient reported by Rieux-Laucat et al 11 who had a homozygous Fas mutation and was severely affected from birth. A novel point mutation in one Fas allele is described in the present report. Truncation of exon 9, representing a critical death domain of Fas, would be expected to cause a functional defect in the Fas apoptotic pathway, as demonstrated in several other patients with Fas mutations. [11] [12] [13] The importance of the Fas exon 8 deletion from one allele in this patient remains uncertain but this region has been proposed to have a role in delivery of distinct intracellular signals associated with Fas function. 6 Absence of the point mutation described in both of our patient's parents makes this the first de novo Fas mutation reported in humans. However, based on the father's clinical history and Fas surface expression, it is likely that he carries an independent Fas defect yet to be identified. Fas surface expression in EBV-transformed cell lines supports the hypothesis that the patient inherited a pre-existing mutant paternal Fas allele and a de novo maternal Fas mutant. As shown in Figure 2 The second reason for this patient's unusually severe disease may be the presence of other interacting genes. Phenotypic expression of the lpr and gld mutations in mice is strongly influenced by other modifying genes, as demonstrated by breeding on to several background strains. 18, 19 Interestingly, aspects of this patient's disease, most notably the prominant eosinophilia, IgA hypergammaglobulinemia, lung infiltration by lymphocytes, mild vasculitis and nephritis but absence of clinical signs of arthritis are strikingly reminiscent of the unique pattern of disease in SJL-lpr and -gld mice. Venous congestion and capillary stasis are common in these animals. Severe interstitial pneumonitis combined with marked reduction in thoracic cavity volume are thought to result in death due to pulmonary insufficiency combined with right-sided heart failure. Additionally, SJLlpr/+ heterozygotes, which show an intermediate lifespan and severity of disease when compared with SJL-lpr/lpr homozygotes and wild-type mice, produce few or no autoantibodies but frequently develop B lineage lymphomas resembling human non-Hodgkin's lymphomas. 19 Finally, specific mutant Fas alleles may have unique properties. In mice, the lpr cg variant can induce autoimmune disorders even in the heterozygous state on the MRL, but not on the CBA, murine background. 20 The lpr cg allele also complements the gld mutation in a way that the original lpr allele does not. This patient's father was diagnosed with immunoglobulin heavy chain disease, a rare disorder of lymphocytes. At least one parent of each of the previously described ALPS patients was an asymptomatic carrier of a Fas defect, although a family history of lymphoma was noted in one case. Defective apoptosis in vitro was demonstrated in these carrier parents, and occasionally in parents with no identified Fas defect. 18 The etiology for the reappearance of DNTs after discontinuation of immunosuppression remains uncertain. Most likely the immunosuppressants used as treatment for GVHD had been controlling the DNT population and once the lymphotoxic agents were discontinued, the DNT population expanded until the patient's reconstituted immune system was able to suppress their expansion. Both the percentage and absolute numbers of DNTs have subsequently normalized and the patient continues to do well clinically 40 months after BMT. These phenotypic differences emphasize the importance of attempting to understand the influence exerted by other human genes in modifying the Fas apoptotic pathway, homozygosity vs heterozygosity, and the identity of specific Fas or Fas ligand defects in both humans and the animal models. As demonstrated here, the manifestations of ALPS can be severe enough to require aggressive medical intervention such as BMT. Ongoing and future studies will better define the prevalence and the range in severity of human disease(s) caused by various Fas mutations. Molecular analysis of Fas defects in patients with ALPS, such as described in this report, should prove useful for genetic counseling of affected families. These observations should also cause clinicians to consider whether potential related BM donors might have subclinical Fas defects themselves.
